What is the 13F Pro Quality Score for MDT?

13F Pro ranks Medtronic plc (MDT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MDT's current score at https://13fpro.ai/company/MDT (free sign-up required for the full ranking).

Which hedge funds own the most MDT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MDT include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/MDT as soon as new 13F filings post.

Where does 13F Pro source MDT data?

All Medtronic plc fundamentals and ownership data come directly from SEC EDGAR. Medtronic plc files with the SEC under CIK 1613103. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MDT in?

Medtronic plc (MDT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives MDT's revenue?

Per Medtronic plc's latest 10-Q filed with the SEC on 2026-09-03, the biggest revenue drivers are: Cardiovascular ($3.9B, +20% YoY); Neuroscience ($2.7B, +10% YoY); Medical Surgical ($2.3B, +10% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/MDT.

What are MDT's largest expenses?

Medtronic plc's latest 10-Q reports these as the largest expense items: Selling, general, and administrative expense ($3.2B, +14% YoY); Research and development expense ($771M, +6% YoY); Amortization of intangible assets ($412M, -10% YoY). Sourced directly from SEC EDGAR filing text for Q1 FY2027 (quarter ended July 31, 2026).

How often is MDT research updated on 13F Pro?

MDT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Medtronic plc(MDT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1613103 MDT stock profile & AI dashboard →

InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

68.5/100

Rank #317 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why MDT Scores 69/100

exact factor attribution · 2026-09-11

MDT's composite is driven by scale and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+6.8 pts

96th pct

Profitability

+3.1 pts

71th pct

Free cash flow

+2.6 pts

68th pct

Earnings quality

+2.5 pts

75th pct

Capital efficiency

+2.2 pts

72th pct

Earnings growth

+0.9 pts

68th pct

Institutional flow

+0.3 pts

56th pct

Revenue growth

+0.2 pts

51th pct

Shareholder dilution

-0.1 pts

49th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

MDT Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Medtronic plc (MDT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MDT at 68.5/100 on a 32-signal composite quality model, placing it at rank #317 of 2,961 stocks — the top 25% of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Medtronic plc reports quarterly revenue of $9.8B, net income of $1.5B, an operating margin of 18.1%. Top institutional holders of MDT by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. MDT trades on the NYSE exchange and files with the SEC under CIK 1613103. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MDT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Medtronic plc directly from SEC EDGAR. Medtronic plc's 13F Pro composite quality score has ranged between 63 and 69 since 2026, currently 68.5 — a stable long-term trajectory across 15 quarterly and live scoring snapshots.

✦

Fun facts about Medtronic plc

Quirks, history, and lore behind MDT — the kind of stuff that makes a stock memorable.

1
The Basics
A mega-cap healthcare company · listed on the NYSE · legally headquartered in Ireland · with the vast majority of its operations and workforce in the United States.
2
The Numbers
Annual revenue of roughly $32 billion and more than 90,000 employees worldwide — one of the largest medical device companies on the planet.
3
The History
Founded in 1949 in Minneapolis by an engineer and his brother-in-law in a garage, it started out repairing medical equipment before pivoting to making it.
4
The Secret
It redomiciled to Ireland in 2015 through a merger that critics called a tax inversion — a move that saved billions but generated plenty of headlines.
5
The Lore
Its co-founder Earl Bakken was inspired by a Popular Electronics article to build the world's first wearable, battery-powered pacemaker in 1957 — changing cardiology forever.
6
The Giveaway
If someone you love has a pacemaker, spinal stimulator, or insulin pump, there's a good chance it has this company's name on it — the undisputed king of implantable medical devices.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving MDT's Business? Latest 10-Q Breakdown

AI-extracted from Medtronic plc's 10-Q filed 2026-09-03 — Q1 FY2027 (quarter ended July 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Medtronic reported Q1 revenue of $9.8B (+14% YoY) driven by Cardiovascular (+20%), Neuroscience (+10%), and Medical Surgical (+10%) growth; diluted EPS $1.14 on GAAP basis, $1.45 non-GAAP.

Biggest Revenue Drivers

Cardiovascular$3.9B+20% YoY

Growth across most divisions; Electrophysiology Therapies +30% driven by pulsed field ablation and Cardiac Rhythm Management; Interventional Cardiology Therapies +7%; CardioVascular Surgery +9%; Peripheral Vascular Health +12%.

Neuroscience$2.7B+10% YoY

Cranial & Spinal Technologies +13% from AiBLE ecosystem adoption; Specialty Therapies +10% from Altaviva and Neurovascular growth; Neuromodulation +5%.

Biggest Revenue Drivers

Total revenue: $9.8B+14% YoY

Cardiovascular$3.9B+20% YoY

Neuroscience$2.7B+10% YoY

Cranial & Spinal Technologies +13% from AiBLE ecosystem adoption; Specialty Therapies +10% from Altaviva and Neurovascular growth; Neuromodulation +5%.

Medical Surgical$2.3B+10% YoY

Surgical & Endoscopy +9% from LigaSure, V-Loc, ProGrip, and Hugo RAS; Acute Care & Monitoring +14% from Nellcor, McGRATH MAC, and Capnography.

Diabetes$843M+17% YoY

U.S. growth from MiniMed Flex commercial launch; international growth from continued MiniMed 780G AID system adoption.

Largest Expense Items

Selling, general, and administrative expense$3.2B+14% YoY

Increase driven by selling expenses in line with sales growth and new product launches and commercialization activities.

Research and development expense$771M+6% YoY

Continued commitment to innovation across therapy solutions.

Amortization of intangible assets$412M-10% YoY

Decrease primarily from $45M accelerated amortization on Cardiovascular intangible assets in prior year.

Margins: Gross margin as a percent of net sales remained flat year-over-year at approximately 65%, supported by favorable pricing and cost-down initiatives that offset unfavorable product mix. Operating profit increased 22% to $1.8B, reflecting strong revenue growth and operating leverage.

Watch Items from the Filing

Hernia mesh litigation: as of August 5, 2026, ~10,500 plaintiffs across coordinated proceedings; first MDL trial verdict on August 4, 2026 awarded $88M in damages; Company has not recorded a liability as ultimate loss remains uncertain pending post-trial challenges and appeals.
Applied Medical antitrust litigation: jury verdict in February 2026 awarded $382M (auto-trebled to ~$1.1B); Company believes award inconsistent with law and plans appeal; ultimate loss not probable and not accrued pending appellate outcome.
MiniMed separation: company retains 90.03% ownership post-March 2026 IPO; plans to complete divestiture within fiscal year 2027; $201M restructuring costs incurred to date with $300-500M expected total charges through fiscal 2029.
Portfolio restructuring: Cardiovascular divisions reorganized into four new divisions (EPT, ICT, CVS, PVH); Diabetes no longer a reportable segment; product line moved from Medical Surgical to Neuroscience, reflecting strategic repositioning.
Acquisitions completed: Scientia Vascular ($681M, June 2026) for neurovascular access; SPR Therapeutics ($654M, July 2026) for peripheral nerve stimulation; CathWorks ($718M, April 2026) for coronary diagnostics.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$9.8B

Net Income

Q2 2026

$1.5B

Free Cash Flow

Q2 2026

$1.3B

Operating Margin

Q2 2026

18.1%

ROIC

Q2 2026

9.0%

D/E Ratio

Q2 2026

0.56

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+8.4% YoY

$36.36BFY 2026

FY23 $31.23BFY24 $32.36BFY25 $33.54BFY26 $36.36B

Net Income

+3.0% YoY

$4.80BFY 2026

FY23 $3.76BFY24 $3.68BFY25 $4.66BFY26 $4.80B

Operating Income

+8.6% YoY

$6.47BFY 2026

FY23 $5.49BFY24 $5.14BFY25 $5.96BFY26 $6.47B

EPS (Diluted)

+3.3% YoY

$3.73FY 2026

FY23 $2.82FY24 $2.76FY25 $3.61FY26 $3.73

Total Assets

+1.5% YoY

$93.03BFY 2026

FY23 $90.95BFY24 $89.98BFY25 $91.68BFY26 $93.03B

Total Debt

-1.9% YoY

$27.96BFY 2026

FY23 $24.36BFY24 $25.02BFY25 $28.52BFY26 $27.96B

Op. Cash Flow

+4.1% YoY

$7.33BFY 2026

FY23 $6.04BFY24 $6.79BFY25 $7.04BFY26 $7.33B

Free Cash Flow

+4.6% YoY

$5.43BFY 2026

FY23 $4.58BFY24 $5.20BFY25 $5.18BFY26 $5.43B

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$36.36B +8.4%	$33.54B +3.6%	$32.36B +3.6%	$31.23B -1.4%	$31.69B +5.2%	$30.12B
Net Income	$4.80B +3.0%	$4.66B +26.8%	$3.68B -2.2%	$3.76B -25.4%	$5.04B +39.7%	$3.61B
Operating Income	$6.47B +8.6%	$5.96B +15.8%	$5.14B -6.2%	$5.49B -4.6%	$5.75B +28.3%	$4.48B
EPS (Diluted)	$3.73 +3.3%	$3.61 +30.8%	$2.76 -2.1%	$2.82 -24.4%	$3.73 +40.2%	$2.66
Total Assets	$93.03B +1.5%	$91.68B +1.9%	$89.98B -1.1%	$90.95B -0.0%	$90.98B -2.3%	$93.08B
Total Debt	$27.96B -1.9%	$28.52B +14.0%	$25.02B +2.7%	$24.36B +1.0%	$24.11B -8.6%	$26.39B
Operating Cash Flow	$7.33B +4.1%	$7.04B +3.8%	$6.79B +12.4%	$6.04B -17.8%	$7.35B +17.7%	$6.24B
Free Cash Flow	$5.43B +4.6%	$5.18B -0.3%	$5.20B +13.5%	$4.58B -23.4%	$5.98B +22.4%	$4.88B

Get alerted when MDT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Medtronic plc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MDT

BlackRock, Inc.
$8.9B114,020,787 sh
VANGUARD CAPITAL MANAGEMENT LLC
$6.6B83,816,735 sh
STATE STREET CORP
$5.0B63,399,315 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.7B34,059,967 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$2.6B19,872,600 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.4B30,192,015 sh
JPMORGAN CHASE & CO
$2.2B27,784,471 sh
BANK OF AMERICA CORP /DE/
$1.7B21,322,401 sh
MORGAN STANLEY
$1.5B19,444,871 sh
DEUTSCHE BANK AG\
$1.4B18,449,877 sh

Fund	Value	Shares
BlackRock, Inc.	$8.9B	114,020,787
VANGUARD CAPITAL MANAGEMENT LLC	$6.6B	83,816,735
STATE STREET CORP	$5.0B	63,399,315
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.7B	34,059,967
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$2.6B	19,872,600
GEODE CAPITAL MANAGEMENT, LLC	$2.4B	30,192,015
JPMORGAN CHASE & CO	$2.2B	27,784,471
BANK OF AMERICA CORP /DE/	$1.7B	21,322,401
MORGAN STANLEY	$1.5B	19,444,871
DEUTSCHE BANK AG\	$1.4B	18,449,877

Companies Similar to MDT

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ABT

ABBOTT LABORATORIES

AI score

Highly similar · 35 shared holders

Capital Research Global Investors BARROW HANLEY MEWHINNEY & STRAUSS LLC STATE FARM MUTUAL AUTOMOBILE INSURANCE CO

AMGN

AMGEN INC

AI score

Very similar · 40 shared holders

Capital Research Global Investors Capital World Investors Aristotle Capital Management, LLC

ABBV

AbbVie Inc.

AI score

Very similar · 40 shared holders

Capital Research Global Investors Capital World Investors Boston Partners

PFE

PFIZER INC

AI score

Very similar · 42 shared holders

Capital World Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO National Pension Service

BMY

BRISTOL MYERS SQUIBB CO

AI score

Very similar · 38 shared holders

M&G Plc National Pension Service PZENA INVESTMENT MANAGEMENT LLC

SYK

STRYKER CORP

AI score

Very similar · 24 shared holders

Capital Research Global Investors Boston Partners National Pension Service

MMM

3M CO

AI score

Very similar · 31 shared holders

Capital World Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO National Pension Service

CVS

CVS HEALTH Corp

AI score

Very similar · 38 shared holders

Capital Research Global Investors Capital World Investors DODGE & COX

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MDT on your watchlist

Track score changes the day Medtronic plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MDT a good stock to buy?

13F Pro's AI-powered analysis of Medtronic plc (MDT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MDT are available on the MDT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MDT is classified as a large company.

Which hedge funds own MDT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MDT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Medtronic plc's investment landscape.